US Brand Name(s): Vizimpro
Use of Dacomitinib in Cancer Treatment
Dacomitinib is to treat the following conditions:
NSCLC (non-small cell lung cancer) has spread (spread to other parts of the body). It’s first-line therapy for individuals with specific EGFR gene mutations in their malignancies.
Dacomitinib is also under research for use in the treatment of various cancers.
Definition from the NCI Drug Dictionary – Detailed scientific definition
Dacomitinib Information on MedlinePlus
A summary of key information regarding this medication in layman’s terms, which may contain the following:
- Cautions about this medicine
- What is the use and how?
- Whom should you consult before taking it?
- What you should know about it before using it?
- other drugs that might interact with it, and possible negative effects.
The Food and Drug Administration approved dacomitinib tablets (VIZIMPRO, Pfizer Pharmaceutical Company)
Drugs are frequently under research to see whether they can assist treat or prevent conditions other than those already prevalent. This patient information leaflet covers uses which have been under authorization. Much of the material, though, might also apply to authorized uses that are being investigated.
